(Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback